Esophageal cancer: What is the life expectancy?
Stage IV Ovarian Cancer
SOURCES:
Image credit: Science Photo Library/Getty Images
American Cancer Society: "Ovarian Cancer Stages," "Radiation Therapy for Ovarian Cancer," "Surgery for Ovarian Cancer," "Chemotherapy for Ovarian Cancer," "Survival Rates for Ovarian Cancer," "Treatment for Stromal Tumors of the Ovary, by Stage," "Treatment of Invasive Epithelial Ovarian Cancers, by Stage," "ACS Patient Programs and Services."
National Cancer Institute: "Dysgerminoma," "Ovarian Germ Cell Tumors Treatment (PDQ) – Patient Version," "Stage IV ovarian epithelial, fallopian tube, and primary peritoneal cancer."
UT Health San Antonio: "Ovarian Cancer: Early detection can help save lives."
Society of Gynecologic Oncology: "Ovarian Cancer Symptoms."
MedlinePlus: "Niraparib," "Bevacizumab Injection."
Ovarian Cancer Research Alliance: "Recurrence," "Clinical Trials 101," "OCRA Clinical Trial Navigation Service," "Exercise and Ovarian Cancer," "Managing Diet for Ovarian Cancer."
Mayo Clinic: "Ovarian cancer."
National Institute on Aging: "What Are Palliative Care and Hospice Care?"
National Health Service (U.K.): "Hysterectomy."
CDC: "Physical Activity: Adults with Chronic Health Conditions and Disabilities."
Target Ovarian Cancer: "Ovarian cancer, diet, and nutrition."
Cancer Research UK: " Coping with ovarian cancer."
Holistic Nursing Practice: "The silent killer: psychological issues in ovarian cancer."
CancerCare.Org: "Financial and Co-Pay Assistance."
Oncology Letters: "Effective treatment of a patient with stage IV ovarian cancer: A case report."
International Journal of Molecular Sciences: "Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo."
What Happens When Metastatic Breast Cancer Affects The Liver?
Metastatic breast cancer (MBC) occurs when breast cancer spreads outside of the breasts to another part of the body, such as the liver.
Approximately 30% of people who receive a diagnosis of early stage breast cancer will go on to develop metastatic, or stage 4, breast cancer. The liver is the third most common organ for breast cancer metastasis.
This article explains what to expect when breast cancer spreads to the liver.
MBC is a late stage cancer that starts in a person's breast tissue. When breast cancer metastasizes, it means that its tissue spreads to distant organs, such as the liver, brain, or bones.
When MBC spreads to another organ, such as the liver, the diagnosis is still breast cancer.
Metastasis refers to the growth of additional cancerous cells beyond the location of the original cancerous tumor.
Breast cancer can metastasize anywhere in the body, most commonly affecting the:
Some research suggests there may be something about a person's liver environment that predisposes their cancer to metastasize to that organ.
However, according to most research, the exact mechanics of how breast cancer spreads specifically to the liver are still not known.
Metavivor, an organization dedicated to researching MBC, states that 1 in 8 women will develop breast cancer during their lifetime. Of those, about 1 in 3 will experience metastasis.
For men, about 1 out of 1,000 will develop breast cancer during their life, but under 2% will experience metastasis.
The liver is the third most common area that MBC affects. Researchers are still not certain exactly how breast cancer spreads to the liver.
The current hypothesis indicates that it spreads to the liver when the cancer cells and the liver are compatible. This is known as the seed and soil hypothesis.
In one 2019 study, researchers found that a few distinguishing factors may place a person at higher risk of developing liver metastasis. These include:
Earlier or more frequent screening for liver metastasis may help improve outlook as a doctor may find the tumor sooner.
Breast cancer that spreads to the liver does not usually cause any symptoms.
A doctor is more likely to find the cancer on a liver function test. The liver function test uses a blood sample to determine the level of liver enzymes and proteins in the blood.
If liver metastasis does cause symptoms, they can include:
There is currently no cure for MBC, so treatment usually focuses on slowing the growth of the tumor and improving a person's quality of life. Treatment can also help increase the person's lifespan.
Treatment for MBC may not be as aggressive as it is in the earlier stages of breast cancer. In the earlier stages of breast cancer, doctors try to remove or destroy the cancer altogether.
If it metastasizes, doctors use medication to help manage the cancer and slow its growth.
According to the American Cancer Society, systematic medications are the main treatment for MBC. These include:
A doctor may suggest a combination of these therapies. They may also recommend radiation therapy or surgery in some situations.
People with MBC can discuss with a doctor the best treatments for them. Some factors to consider include:
There is no cure for MBC. Someone with MBC that has spread to the liver may live for several more years with successful treatment.
Treatment tends to focus on slowing the growth and spread as well as managing the symptoms.
Based on their age or overall health, a person may decide to discontinue treatment. In these cases, the person should talk with a treatment team and their family about end-of-life care.
How long can you live with metastasis to the liver?According to the American Cancer Society, the 5-year survival rate is about 30% for distant cancer, which it defines as "cancer has spread to distant parts of the body such as the lungs, liver or bones."
Specifically, the 3-year survival rate for breast cancer liver metastasis is about 38%, which is similar to the rate for lung metastasis but not as favorable as bone metastasis.
With treatment, a person may be able to live for several years. The person should talk with a doctor about their individual outlook, as several factors can affect successful treatment.
There is currently no cure for MBC that spreads to the liver.
With treatment, people may be able to slow the growth of the tumor and improve their quality of life. A person can talk with a doctor about the best treatment options for them.
Buttin Reviews Results From PAOLA-1 In Ovarian Cancer
Barbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.
Barbara Buttin, MD, a gynecologic oncologist at City of Hope Chicago, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.
PAOLA-1 was a randomized, double-blind, phase 3 study of the PARP inhibitor with chemotherapy and bevacizumab compared with placebo in patients with advanced FIGO stage IIIb-IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer. In 2020, results from this study led to the FDA approval of olaparib plus bevacizumab for the treatment of ovarian, fallopian tube, or primary peritoneal cancers.
Initial results from PAOLA-1 were published in the New England Journal of Medicine and showed that olaparib and bevacizumab achieved 41% reduction in the risk of disease progression or death compared with placebo (HR, 0.59; 95% CI, 0.49-0.72; P <.001). The median progression-free survival (PFS) observed with olaparib plus bevacizumab was 22.1 months versus 16.6 months with bevacizumab.
0:09The PAOLA-1 trial was the international trial that showed us the benefit of using the combination of PARP and bevacizumab, specifically in the population of ovarian cancer patients with HRD. Again, we you know that our BRCA-positive patients have the best prognosis, and our BRCA-negative/HRD-negative patients have the worst prognosis in terms of progression-free and overall survival. PAOLA-1 showed us that PARP with bevacizumab improves outcomes in both groups, most importantly for the HRD-positive population, and that's where the indication was made.
1:05The post hoc analysis showed us that basically, progression while on olaparib, the PARP inhibitor and bevacizumab is a core prognostic sign, which of course, makes sense in that population. The from first to second progression in the patients who received PRAP vs placebo was significantly different in that group. It is worth pushing these patients towards the doublet in in terms of maintenance therapy to prolong that disease-free survival between recurrences as much as possible, and that's kind of what the takeaway was here.
Comments
Post a Comment